Emerging drugs for endometriosis.

Area of Science:

• Gynecology
• Reproductive Medicine
• Pharmacology

Background:

• Endometriosis treatments aim to suppress ovarian steroids, inducing hypoestrogenism to atrophy ectopic endometrium.
• Current therapies (GnRH analogues, danazol, progestogens, OCPs) relieve pain but often recur post-treatment and cause side effects.
• Existing treatments are unsuitable for patients desiring pregnancy due to ovulation inhibition.

Purpose of the Study:

• To review current and emerging therapeutic strategies for endometriosis management.
• To identify treatments with improved long-term safety and efficacy profiles.
• To explore novel approaches targeting endometriosis aetiopathogenesis, including ovarian-sparing and immunomodulatory options.

Main Methods:

• Review of existing medical treatments for endometriosis, including hormonal therapies and intrauterine devices.
• Evaluation of emerging therapeutic targets and agents, such as aromatase inhibitors, antiprogestogens, and immunomodulators.
• Analysis of preliminary data and ongoing research in endometriosis treatment development.

Main Results:

• Gonadotrophin-releasing hormone (GnRH) analogues, danazol, progestogens, and oral contraceptives are effective but have limitations.
• Levonorgestrel-releasing intrauterine devices show promise for long-term management and symptom relief.
• Mifepristone and aromatase inhibitors are under investigation as potential alternatives with improved tolerability and ovarian function preservation.
• Anti-inflammatory drugs and immune modulators (e.g., TNF-binding protein-1, IL-12) demonstrate efficacy in preclinical models.

Conclusions:

• Novel therapeutic strategies are needed to overcome limitations of current endometriosis treatments.
• Ovarian-sparing treatments like aromatase inhibitors and immunomodulatory agents represent promising future directions.
• Further research into endometriosis aetiopathogenesis is crucial for developing curative or preventive therapies.